SAMHSA is accepting applications for $196 million to treat opioid use disorder through its Targeted Capacity Expansion: Medication Assisted Treatment-Prescription Drug Opioid Addiction Program (Short Title: MAT-PDOA) totaling up to $196 million over 3 years. The new funding will expand access to medication-assisted treatment for people with opioid use disorder. SAMHSA expects to fund up to 125 grantees up to $524,670 per year for up to 3 years. The application due date is July 9, 2018 by 11:59 p.m. (ET).
|
SAMHSA is accepting applications for the Certified Community Behavioral Health Clinic Expansion Grants (Short Title: CCBHC Expansion Grants) totaling up to $95.9 million over the next two years. The purpose of this program is to increase access to and improve the quality of community behavioral health services through the expansion of CCBHCs. SAMHSA expects to fund up to 25 grantees with up to $2 million per year for up to 2 years. The application due date is July 9, 2018 by 11:59 p.m. (ET).
SAMHSA is accepting applications for the Infant and Early Childhood Mental Health Grant Program totaling up to $23.4 million over the next 5 years. The purpose of this program is to improve outcomes for young children by developing, maintaining, or enhancing infant and early childhood mental health promotion, intervention, and treatment services. SAMHSA expects to fund up to nine grantees with up to $500,000 per year for up to 5 years. The application due date is June 29, 2018 by 11:59 p.m. (ET).
SAMHSA is accepting applications for the Providers Clinical Support System – Universities (Short Title: PCSS - Universities) grants totaling up to $10.8 million over the next three years. The purpose of this program is to expand/enhance access to medication-assisted treatment (MAT) services for persons with an opioid use disorder seeking or receiving MAT through ensuring the education and training of students in the medical, physician assistant and nurse practitioner fields. SAMHSA expects to fund up to 24 grantees, up to $150,000 per year for up to 3 years. The application due date is July 25, 2018 by 11:59 p.m. (ET).
Suicide is a serious public health problem that causes immeasurable pain, suffering, and loss to individuals, families, and communities nationwide. The causes of suicide are complex and determined by multiple combinations of factors, such as mental illness, substance abuse, painful losses, exposure to violence, and social isolation. If you need to talk to someone, please call the National Suicide Prevention Lifeline at 1-800-273-8255. SAMHSA offers additional suicide prevention information and resources.
|
Each September, SAMHSA sponsors National Recovery Month (Recovery Month) to increase awareness and understanding of mental and substance use disorders, and to celebrate individuals living in recovery. The Toolkit and PSAs can be used to organize events, issue proclamations, and increase public awareness. Learn more about Recovery Month 2018 and how you can get involved.
SAMHSA has published an update to its Opioid Overdose Prevention Toolkit, which is designed to help healthcare providers, families and other community members prevent overdose deaths related to opioid use. The toolkit addresses several factors that can lead to an opioid overdose death. The toolkit also discusses when and how to use naloxone, a medication that can reverse an opioid overdose. People with opioid use disorders can weigh treatment options by visiting SAMHSA's treatment locator, https://findtreatment.samhsa.gov. A Spanish language version of the toolkit is expected to be available in late July.
SAMHSA announces the release of the Spanish translation of the fact sheet, Finding Quality Treatment for Substance Use Disorders. This fact sheet serves as a guide for individuals seeking behavioral health treatment. It outlines the three necessary steps to complete prior to utilizing a treatment center. It also lists the five signs of a quality treatment center, which include a review of the accreditation, medication, evidence-based practices, position on the role of families, and support networks. The English version is also available.
The FDA is urging Naloxone carriers to check their product against a national recall list. The maker of the drug, Hospira, has issued a voluntary recall of the opioid overdose reversal drug Naloxone due to the presence of loose particulate matter in the syringe plunger. Please inform the healthcare professionals in your network immediately. The FDA includes information on the specific product lot numbers affected by this recall.
Emergency medical services personnel, firefighters, and police officers are often the first on the scene to aid those experiencing disasters and other traumatic situations. Research shows that repeated exposure to such situations, the fast-paced nature of these jobs, and institutional factors can take a toll on first responders' health. This edition of the SAMHSA Supplemental Research Bulletin may be helpful to first responders in maintaining their own health and managers seeking to support the behavioral health of their teams.
The Atlantic hurricane season of 2017 was one of the most active on record. The latest installment of the SAMHSA Disaster Behavioral Health Information Series focuses on hurricane preparedness, response, and recovery, as well as behavioral health issues related to hurricanes.
June 19, 2018 | 2 – 3 p.m. Eastern Time
This is the final webcast in The Power of Perceptions and Understanding: Changing How We Deliver Treatment and Recovery Services series. This webcast aims to educate healthcare professionals about the problems of discriminatory practices and inaccurate perceptions in dealing with individuals with substance use disorders and related conditions. You may also view and apply for free CME/CE credits of previously held webcasts in this series. Earn 1.0 free CME/CE credit for attending this one hour webinar.
|
| 
